We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+0.86%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$139M
AUM Growth
-$16.2M
Cap. Flow
-$1.33M
Cap. Flow %
-0.96%
Top 10 Hldgs %
71.95%
Holding
68
New
1
Increased
14
Reduced
5
Closed
5

Top Buys

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$967K
2
DCGO icon
DocGo
DCGO
+$753K
3
PHR icon
Phreesia
PHR
+$306K
4
GOSS icon
Gossamer Bio
GOSS
+$281K
5
NKTR icon
Nektar Therapeutics
NKTR
+$276K

Top Sells

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$2.04M
2
BMY icon
Bristol-Myers Squibb
BMY
+$806K
3
PGNY icon
Progyny
PGNY
+$755K
4
BIIB icon
Biogen
BIIB
+$544K
5
TGTX icon
TG Therapeutics
TGTX
+$285K

Sector Composition

Rank Sector Weight
1 Healthcare 94.92%
2 Energy 2.82%
3 Consumer Staples 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GTHX
51
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$304K 0.22%
40,000
– –
KNSA icon
52
Kiniksa Pharmaceuticals
KNSA
$4.84B
$298K 0.21%
30,000
– –
PHR icon
53
Phreesia
PHR
$659M
$264K 0.19%
+10,000
New +$306K
ISEE
54
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$252K 0.18%
15,000
– –
TPTX
55
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$215K 0.15%
8,000
– –
IFRX icon
56
InflaRx
IFRX
$272M
$128K 0.09%
70,000
– –
ELTX icon
57
Elicio Therapeutics
ELTX
$79.8M
$115K 0.08%
5,439
– –
AWH
58
DELISTED
Aspira Women's Health Inc. Common Stock
AWH
$107K 0.08%
6,874
– –
LSF icon
59
Laird Superfood
LSF
$47.4M
$101K 0.07%
28,000
+10,000
+56% +$68K
YTEN
60
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
$99K 0.07%
781
– –
SIEN
61
DELISTED
Sientra, Inc.
SIEN
$89K 0.06%
4,000
– –
CNCE
62
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$67K 0.05%
20,000
– –
AKBA icon
63
Akebia Therapeutics
AKBA
$343M
$14K 0.01%
20,000
-80,000
-80% -$171K
PFE icon
64
Pfizer
PFE
$141B
– –
-4,000
Closed -$236K
PGNY icon
65
Progyny
PGNY
$2.51B
– –
-15,000
Closed -$755K
TGTX icon
66
TG Therapeutics
TGTX
$8.39B
– –
-15,000
Closed -$285K
TXMD icon
67
TherapeuticsMD
TXMD
$23.8M
– –
-1,000
Closed -$18K
ARNA
68
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-22,000
Closed -$2.04M
1 2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q1 2022 Portfolio in Review

As of Q1 2022, Birchview Capital held 68 positions worth $139M, down 10% from $155M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Birchview Capital's Q1 2022 filing shows 1 new, 14 increased, 5 reduced and 5 closed positions. Its largest new stake was Phreesia: 10,000 shares worth $264K. The largest sale was Arena Pharmaceuticals Inc, an estimated $2.04M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q1 2022 buy was Phreesia: 10,000 shares worth $264K.
  • Birchview Capital added most to Soleno Therapeutics in Q1 2022, an estimated $967K increase.
  • Birchview Capital's biggest Q1 2022 reduction was Bristol-Myers Squibb, cutting an estimated $806K.
  • Birchview Capital fully exited Arena Pharmaceuticals Inc in Q1 2022, selling an estimated $2.04M.
  • Birchview Capital's ten largest holdings make up 72% of its $139M portfolio in Q1 2022.
  • Birchview Capital opened 1 new position and closed 5 in Q1 2022.
  • Birchview Capital's portfolio value fell 10% quarter-over-quarter to $139M.

Based on Birchview Capital's 13F filing for Q1 2022, filed 13 May 2022.